CGC (Canopy Growth) Forward Rate of Return (Yacktman) %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGC Canopy Growth Corp CGC
40 GF Score
Price $0.99
GF Value $0.67
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Canopy Growth Forward Rate of Return (Yacktman) %?

Canopy Growth CGC -1.03% 40 Forward Rate of Return (Yacktman) % is 0.00% as of Jun. 2026. GuruFocus rates CGC with a GF Score™ of 40/100 and a GF Value™ of $0.67 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 634 Drug Manufacturers companies, Canopy Growth ranks worse than 157728.55% on this metric.

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Canopy Growth's forward rate of return for was 0.00%.

The historical rank and industry rank for Canopy Growth's Forward Rate of Return (Yacktman) % or its related term are showing as below:

During the past 13 years, Canopy Growth's highest Forward Rate of Return was 20.00. The lowest was -46.22. And the median was 18.15.

CGC's Forward Rate of Return (Yacktman) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.2
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Canopy Growth  (NAS:CGC) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Canopy Growth Forward Rate of Return (Yacktman) % Related Terms


Canopy Growth Forward Rate of Return (Yacktman) % Historical Data

* Premium members only.

The historical data trend for Canopy Growth's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Canopy Growth Forward Rate of Return (Yacktman) % Chart

Canopy Growth Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Canopy Growth Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CGC vs ZTS: Forward Rate of Return (Yacktman) % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Canopy Growth Forward Rate of Return (Yacktman) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Canopy Growth's Forward Rate of Return (Yacktman) % falls into.


CGC
40GF Score
Canopy Growth Corp CGC
Forward Rate of Return (Yacktman) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Canopy Growth Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Canopy Growth's Forward Rate of Return of Jun. 2026 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.95+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Forward Rate of Return (Yacktman) % of 0.00% mean?
Canopy Growth (CGC) has a Forward Rate of Return (Yacktman) % of 0.00% as of Jun. 2026. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Canopy Growth and its competitors. According to the industry distribution chart, Canopy Growth ranks #999999 out of 634 companies in the Drug Manufacturers industry.
Is Canopy Growth's Forward Rate of Return (Yacktman) % too high?
Canopy Growth's current Forward Rate of Return (Yacktman) % is 0.00%. Based on the distribution chart, Canopy Growth ranks #999999 out of 634 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Canopy Growth has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's Forward Rate of Return (Yacktman) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #999999 out of 634 companies for Forward Rate of Return (Yacktman) %. This places Canopy Growth in the lower half of its industry. The industry median Forward Rate of Return (Yacktman) % is 6.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Drug Manufacturers company?
The median Forward Rate of Return (Yacktman) % among Drug Manufacturers companies is 6.20, based on 634 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Canopy Growth and its competitors. For the Drug Manufacturers industry, the median Forward Rate of Return (Yacktman) % is 6.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canopy Growth's current Forward Rate of Return (Yacktman) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (CGC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $0.99 — trading 47.5% above its estimated fair value. The current Forward Rate of Return (Yacktman) % is 0.00%. Canopy Growth's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For Canopy Growth (CGC), the current Forward Rate of Return (Yacktman) % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Canopy Growth (CGC) Overvalued in 2026?

Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued. The current stock price of $0.99 is trading 47.5% above its estimated GF Value™ of $0.67. GuruFocus considers Canopy Growth to be Significantly Overvalued.

Key valuation signals for CGC:

  • Forward Rate of Return (Yacktman) %: 0.00%
  • GF Value™: $0.67 vs. price of $0.99 (47.5% above fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the CGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Canopy Growth Business Description

Other Exchanges 11L:GermanyWEED:Canada
Address 1 Hershey Drive, Smiths Falls, ON, CAN, K7A 0A8
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
40GF Score

Get the complete analysis for CGC

Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.99
Price
$0.67
GF Value